Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs

Journal of Medicinal Chemistry

Volumn 53, Issue 21, 2010, Pages 7767-7777

  Kularatne, Sumith A ^a   Venkatesh, Chelvam ^a   Santhapuram, Hari Krishna R ^b   Wang, Kevin ^b   Vaitilingam, Balasubramanian ^a   Henne, Walter A ^a   Low, Philip S ^a  

^a PURDUE UNIVERSITY   (United States)

^b Endocyte Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 (1,3 DICARBOXYPROPYL)UREIDO]PENTANEDIOIC ACID; ANTINEOPLASTIC AGENT; PRODRUG; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL KILLING; CYTOTOXICITY; DISULFIDE BOND; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; LIGAND BINDING;

ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; GLUTAMATE CARBOXYPEPTIDASE II; GLUTARATES; HUMANS; LIGANDS; MALE; MOLECULAR TARGETED THERAPY; PRODRUGS; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 78149279338     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100729b     Document Type: Article

References (48)

1. Van der Hul, R. L.; Seynaeve, C.; van Gell, B. N.; Verweij, J. Low dose of methotrexate and vinblastine, given weekly to patients with Desmoid tumors, is associated with major toxicity Sarcoma 2003, 7, 153-157
2. Onyenadum, A.; Gogas, H.; Markopoulos, C.; Bafaloukos, D.; Aravantinos, G.; Mantzourani, M.; Koutras, A.; Tzorakoelefterakis, E.; Xiros, N.; Makatsoris, T.; Fountzilas, G.; Kalofonos, H. P. Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer J. Chemother. 2007, 19, 582-589
3. Rahmani, R.; Zhou, X. J. Pharmacokinetics and metabolism of vinca alkaloids Cancer Surv. 1993, 17, 269-281
4. Rowinsky, E. K.; Chaudhry, V.; Cornblath, D. R.; Donehower, R. C. Neurotoxicity of Taxol J. Natl. Cancer Inst. Monogr. 1993, 15, 107-115
5. Rowinsky, E. K.; Eisenhauer, E. A.; Chaudhry, V.; Arbuck, S. G.; Donehower, R. C. Clinical toxicities encountered with paclitaxel (Taxol) Semin. Oncol. 1993, 20, 1-15
6. Ivachtchenko, A. V.; Kiselyov, A. S.; Tkachenko, S. E.; Ivanenkov, Y. A.; Balakin, K. V. Novel mitotic targets and their small-molecule inhibitors Curr. Cancer Drug Targets 2007, 7, 766-784
7. Druker, B. J. Translation of the Philadelphia chromosome into therapy for CML Blood 2008, 112, 4808-4817
8. Rabatti, D. The discovery of antiangiogenic molecules: a historical review Curr. Pharm. Des. 2009, 15, 345-352
9. Li, W. W.; Hutnik, M.; Gehr, G. Antiangiogenesis in haematological malignancies Br. J. Hamaetol. 2008, 143, 622-631
10. Mauro, M. J. Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia: When to change? A perspective in 2009 Curr. Opin. Hematol. 2009, 16, 135-139
11. Breccia, M.; Frustaci, A. M.; Cannella, L.; Soverini, S.; Stefanizzi, C.; Federico, V.; Grammatico, S.; Santopietro, M.; Alimena, G. Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: An emerging problem? Cancer Chemother. Pharmacol. 2009, 64, 195-197
12. Ojima, I. Guided molecular missiles for tumor-targeting chemotherapy-case studies using the second-generation taxoids as warheads Acc. Chem. Res. 2008, 41, 108-119
13. Balhorn, R.; Hok, S.; Burke, P. A.; Lightstone, F. C.; Cosman, M.; Zemla, A.; Mirick, G.; Perkins, J.; Natarajan, A.; Corzett, M.; DeNardo, S. J.; Albrecht, H.; Gregg, J. P.; DeNardo, G. L. Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: Initial application to lymphoma/leukemia Clin. Cancer Res. 2007, 15, 5621s-5628s
14. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy Nat. Rev. Cancer 2002, 2, 750-763
15. Low, P. S.; Kularatne, S. A. Folate-targeted therapeutic and imaging agents for cancer Curr. Opin. Chem. Biol. 2009, 13, 256-262
16. Larsen, A. K.; Escargueil, A. K.; Skladanowski, A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents Pharmacol. Ther. 2000, 85, 217-229
17. Isaken, K.; Jonsson, R.; Omdal, R. Anti-CD20 treatment in primary Sjögren's syndrome Scand. J. Immunol. 2008, 68, 554-564
18. Gisselbrecht, C. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting Br. J. Hamaetol. 2008, 143, 607-621
19. Hall, P. C.; Cameron, D. A. Current perspective-trastuzumab Eur. J. Cancer 2009, 45, 12-18
20. Jean, G. W.; Shah, S. R. Epiderm growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer Pharmacotherapy 2008, 28, 742-754
21. Zwanziger, D.; Beck-Sickinger, A. G. Radiometal targeted tumor diagnosis and therapy with peptide hormones Curr. Pharm. Des. 2008, 14, 2385-2400
22. Schally, A. V. New approaches to the therapy of various tumors based on peptide analogues Horm. Metab. Res. 2008, 40, 315-322
23. Nishimura, Y.; Bereczky, B.; Ono, M. The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines Histochem. Cell Biol. 2007, 127, 541-553
24. Ye, X.; Yang, D. Recent advances in biological strategies for targeted drug delivery Cardiovasc. Hematol. Disord. Drug Targets 2009, 9, 206-221
25. Yan, H.; Tram, K. Glycotargeting to improve cellular delivery efficiency of nucleic acids Glycoconjugate J. 2007, 24, 107-123
26. Irache, J. M.; Salman, H. H.; Gamazo, C.; Espuelas, S. Mannose-targeted systems for the delivery of therapeutics Expert Opin. Drug Delivery 2008, 5, 703-724
27. Corti, A.; Curnis, F.; Arap, W.; Pasqualini, R. The neovasculature homing motif NGR: More than meets the eye Blood 2008, 112, 2628-2635
28. Gupta, Y.; Kohli, D. V.; Jain, S. K. Vitamin B12-mediated transport: A potential tool for tumor targeting of antineoplastic drugs and imaging agents Crit. Rev. Ther. Drug Carrier Syst. 2008, 25, 347-379
29. Kularatne, S. A.; Wang, K.; Santhapuram, H. K.; Low, P. S. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand Mol. Pharmaceutics 2009, 6, 780-789
30. Ghosh, A.; Heston, W. D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer J. Cell Biochem. 2004, 91, 528-539
31. Chang, S. S.; O'Keefe, D. S.; Bacich, D. J.; Reuter, V. E.; Heston, W. D.; Gaudin, P. B. Prostate-specific membrane antigen is produced in tumor-associated neovasculature Clin. Cancer Res. 1999, 5, 2674-2681
32. Liu, H.; Rajasekaran, A. K.; Moy, P. Constitutive and antibody-induced internalization of prostate-specific membrane antigen Cancer Res. 1998, 58, 4055-4060
33. Silver, D. A.; Pellicer, I.; Fair, W. R.; Heston, W. D.; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues Clin. Cancer Res. 1997, 3, 81-85
34. Slusher, B. S.; Tsai, G.; Yoo, G.; Coyle, J. T. Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated α-linked acidic dipeptidase (NAALADase) J. Comp. Neurol. 1992, 315, 217-229
35. 99mTc-radioimaging agents Mol. Pharmaceutics 2009, 6, 790-800
36. Vlahov, I. R.; Wang, Y.; Kleindl, P. J.; Leamon, C. P. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part II: Folic acid conjugates of tubulysins and their hydrazides Bioorg. Med. Chem. Lett. 2008, 18, 4558-4561
37. Vlahov, I. R.; Santhapuram, H. K.; Kleindl, P. J.; Howard, S. J.; Stanford, K. M.; Leamon, C. P. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide Bioorg. Med. Chem. Lett. 2006, 16, 5093-5096
38. Henne, W. A.; Doorneweerd, D. D.; Hilgenbrink, A. R.; Kularatne, S. A.; Low, P. S. Synthesis and activity of a folate peptide camptothecin prodrug Bioorg. Med. Chem. Lett. 2006, 16, 5350-5355
39. Pessah, N.; Reznik, M.; Shamis, M.; Yantiri, F.; Xin, H.; Bowdish, K.; Shomron, N.; Ast, G.; Shabat, D. Bioactivation of carbamate-based 20(S)-camptothecin prodrugs Bioorg. Med. Chem. 2004, 12, 1859-1866
40. de Groot, F. M.; Busscher, G. F.; Aben, R. W.; Scheeren, H. W. Novel 20-carbonate linked prodrugs of camptothecin and 9-aminocamptothecin designed for activation by tumour-associated plasmin Bioorg. Med. Chem. Lett. 2002, 12, 2371-2376
41. Kratz, F.; Muller, I. A.; Ryppa, C.; Warnecke, A. Prodrug strategies in anticancer chemotherapy Chem. Med. Chem. 2008, 3, 20-53
42. Sega, E. I.; Low, P. S. Tumor detection using folate receptor-targeted imaging agents Cancer Metastasis Rev. 2008, 27, 655-664
43. Zhao, X.; Li, H.; Lee, R. J. Targeted drug delivery via folate receptor Expert Opin. Drug Delivery 2008, 5, 309-319
44. Tarragó-trani, M. T.; Storrie, B. Alternative routes for drug delivery to the cell interior: Pathways to the Golgi apparatus and endoplasmic reticulum Adv. Drug Delivery Rev. 2007, 59, 782-797
45. Whitehead, K. A.; Langer, R.; Anderson, D. G. Knocking down barriers: advances in siRNA delivery Nat. Rev. Drug Discovery 2009, 8, 129-138
46. Aigner, A. Cellular delivery in vivo of siRNA-based therapeutics Curr. Pharm. Des. 2008, 14, 3603-3619
47. Oh, Y. K.; Park, T. G. siRNA delivery systems for cancer treatment Adv. Drug Delivery Rev. 2009, 61, 850-862
48. Walchli, S.; Sioud, M. Vector-based delivery of siRNAs: in vitro and in vivo challenges Front. Biosci. 2008, 13, 3488-3493